PROK
ProKidney Corp. NASDAQ Listed Jun 30, 2021$1.63
Pre-mkt
$1.66
+1.84%
Mkt Cap $548.1M
52w Low $1.45
8.9% of range
52w High $3.48
50d MA $1.73
200d MA $2.11
P/E (TTM)
—
EV/EBITDA
—
P/B
0.7x
Debt/Equity
0.0x
ROE
6.8%
P/FCF
-1.6x
RSI (14)
53.50
ATR (14)
$0.08
Beta
1.86
50d MA
$1.73
200d MA
$2.11
Avg Volume
1.4M
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
2000 Frontis Plaza Blvd. · Winston-Salem, NC 27103 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | AMC | -0.13 | -0.14 | -7.7% | 1.66 | +0.0% | -3.0% | -3.7% | +9.0% | +3.6% | +0.0% | — |
| Mar 18, 2026 | AMC | -0.16 | -0.14 | +12.5% | 2.08 | -1.0% | -6.2% | -1.0% | +0.5% | -7.7% | +2.2% | — |
| Nov 10, 2025 | AMC | -0.12 | -0.12 | +0.0% | 2.70 | +3.0% | +3.7% | -4.3% | -14.9% | +5.7% | -6.6% | — |
| Aug 12, 2025 | AMC | -0.14 | -0.13 | +7.1% | 2.24 | +0.4% | +5.8% | +2.1% | -2.5% | +7.6% | -8.3% | — |
| May 12, 2025 | AMC | -0.16 | -0.13 | +18.8% | 0.75 | +1.4% | +15.8% | -11.2% | +10.2% | -5.1% | +0.2% | — |
| Mar 17, 2025 | AMC | -0.14 | -0.17 | -21.4% | 1.04 | -1.0% | -6.8% | +2.2% | -4.9% | +1.9% | +6.2% | — |
| Nov 12, 2024 | AMC | -0.14 | -0.14 | +0.0% | 2.05 | +3.4% | +1.0% | +3.9% | -20.9% | -2.4% | +8.4% | — |
| Aug 9, 2024 | AMC | -0.17 | -0.16 | +5.9% | 2.18 | +5.5% | -4.6% | +9.1% | +0.4% | +4.8% | +0.4% | — |
| May 10, 2024 | AMC | -0.25 | -0.16 | +36.0% | 2.81 | +3.2% | +9.6% | +33.8% | -4.9% | -3.3% | +7.1% | — |
| Mar 21, 2024 | AMC | -0.19 | -0.09 | +52.6% | 1.37 | +1.5% | +2.2% | +2.9% | +10.4% | -1.3% | +4.5% | — |
| Nov 14, 2023 | AMC | -0.19 | -0.18 | +5.3% | 1.52 | -2.0% | -8.6% | -11.5% | -1.6% | +45.5% | +5.7% | — |
| Aug 10, 2023 | AMC | -0.41 | -0.14 | +65.9% | 12.72 | +1.9% | +1.7% | -9.0% | -6.4% | -6.5% | -5.1% | — |
| May 11, 2023 | AMC | -0.39 | -0.16 | +59.0% | 9.02 | +2.0% | +1.0% | +1.2% | +5.5% | +4.7% | -7.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 15 | UBS | Maintains | Buy → Buy | — | $3.69 | $4.25 | +15.2% | -8.7% | +10.7% | -5.6% | -10.5% | +2.2% |
| Jul 14 | Guggenheim | Maintains | Buy → Buy | — | $4.54 | $4.78 | +5.3% | -18.7% | -8.7% | +10.7% | -5.6% | -10.5% |
| Jul 9 | Citigroup | Maintains | Buy → Buy | — | $3.73 | $5.81 | +55.8% | +16.4% | +19.4% | -12.4% | -18.7% | -8.7% |
| Jun 30 | BofA Securities | Downgrade | Neutral → Underperform | — | $0.67 | $0.64 | -3.8% | -11.5% | -4.5% | +2.4% | +10.1% | -4.8% |
| Sep 4 | BofA Securities | Maintains | Neutral → Neutral | — | $2.40 | $2.31 | -3.8% | -9.2% | +8.7% | -1.7% | +2.6% | +0.8% |
| Jun 10 | Jefferies | Maintains | Buy → Buy | — | $3.19 | $3.31 | +3.8% | -5.3% | -19.9% | +23.6% | -0.7% | -8.1% |
| May 29 | BofA Securities | Maintains | Neutral → Neutral | — | $3.71 | $3.70 | -0.3% | +6.7% | +6.1% | -17.1% | -12.9% | +5.9% |
| Jan 2 | BofA Securities | Downgrade | Buy → Neutral | — | $1.78 | $1.74 | -2.2% | -3.9% | -12.3% | +0.7% | -3.3% | +1.4% |
| Dec 21 | Jefferies | Maintains | Buy → Buy | — | $7.30 | $7.45 | +2.0% | +3.2% | -1.5% | -12.0% | -5.8% | -11.1% |
| Nov 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $10.55 | $10.65 | +0.9% | +0.9% | +6.9% | -1.6% | -3.2% | -3.6% |
| Oct 18 | UBS | Maintains | Buy → Buy | — | $9.97 | $10.30 | +3.3% | +0.0% | +1.8% | +1.8% | -0.6% | -1.9% |
| Oct 14 | Citigroup | Maintains | Buy → Buy | — | $10.25 | $10.50 | +2.4% | -3.3% | +0.6% | +0.0% | +1.8% | +1.8% |
| Sep 2 | Evercore ISI | Maintains | Outperform → Outperform | — | $9.67 | $10.00 | +3.4% | +5.5% | -31.4% | +11.4% | +4.7% | +20.4% |
No insider trades available.
8-K · 8.01
!! High
ProKidney Corp. -- 8-K 8.01: Material Event / Announcement
May 15
8-K
Unknown — 8-K Filing
ProKidney's positive Phase 2 results and FDA accelerated approval pathway alignment suggest potential faster commercialization, which could significantly reduce execution risk and create substantial shareholder value if regulatory approvals proceed as planned.
Mar 18
8-K · 8.01
!! High
ProKidney Corp. Class A -- 8-K 8.01: Material Event / Announcement
I need more information to complete this task. The summary appears to be incomplete—it cuts off mid-sentence at "The information set forth in the second paragraph of" without specifying what announcement or material event occurred.
Could you provide the complete summary of the filing?
Feb 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 17,634,002 | $40M | Added | Dec 2025 |
| 2 | Millennium Management | 2,271,577 | $4M | Added | Mar 2026 |
| 3 | Renaissance Technologies Llc | 1,250,794 | $2M | Added | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 1,146,937 | $2M | New | Mar 2026 |
| 5 | Marshall Wace, Llp | 1,011,744 | $2M | Added | Mar 2026 |
| 6 | Bank Of America Corp /de/ | 753,412 | $1M | Added | Mar 2026 |
| 7 | Jane Street Group, Llc | 493,849 | $1M | Added | Dec 2025 |
| 8 | Woodline Partners Lp | 500,000 | $895K | — | Mar 2026 |
| 9 | Two Sigma Investments, Lp | 346,382 | $620K | Reduced | Mar 2026 |
| 10 | Ubs Group Ag | 334,546 | $599K | Reduced | Mar 2026 |
| 11 | Amundi | 291,708 | $522K | New | Mar 2026 |
| 12 | Northern Trust Corp | 241,580 | $432K | — | Mar 2026 |
| 13 | Susquehanna International Group, Llp | 204,488 | $366K | Reduced | Mar 2026 |
| 14 | Barclays Plc | 146,284 | $262K | Reduced | Mar 2026 |
| 15 | Virtus Investment Advisers, Llc | 123,388 | $221K | Added | Mar 2026 |
| 16 | Hrt Financial Lp | 118,981 | $212K | New | Mar 2026 |
| 17 | Entrypoint Capital, Llc | 82,862 | $148K | Added | Mar 2026 |
| 18 | Point72 Asset Management | 65,578 | $117K | Added | Mar 2026 |
| 19 | Hudson Bay Capital Management Lp | 45,056 | $101K | New | Dec 2025 |
| 20 | Catalyst Funds Management Pty Ltd | 47,800 | $86K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 13
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Morgan Stanley Discovery Portfolio | 1,082,616 | $2M | Mar 2026 |
| 2 | Fidelity Extended Market Index Fund | 553,164 | $1M | Feb 2026 |
| 3 | Schwab U.S. Small-Cap ETF | 504,944 | $924K | May 2026 |
| 4 | Fidelity Total Market Index Fund | 192,034 | $351K | May 2026 |
| 5 | Fidelity Series Total Market Index Fund | 157,889 | $289K | May 2026 |
| 6 | Virtus LifeSci Biotech Clinical Trials ETF | 127,478 | $252K | Jan 2026 |
| 7 | Fidelity Nasdaq Composite Index Fund | 86,948 | $195K | Feb 2026 |
| 8 | Schwab U.S. Broad Market ETF | 64,764 | $119K | May 2026 |
| 9 | Schwab Total Stock Market Index Fund | 49,000 | $97K | Jan 2026 |
| 10 | Victory Extended Market Index Fund | 11,538 | $23K | Jan 2026 |
| 11 | Small Cap Core Fund | 5,668 | $10K | Mar 2026 |
| 12 | State Street Balanced Index Fund | 1,229 | $2K | Mar 2026 |
| 13 | Knights of Columbus U.S. ALL CAP INDEX FUND | 602 | $1K | Jan 2026 |
Valuation
Market Cap
$548.1M
Enterprise Value
-$51.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.27x
P/B
0.73x
P/S
616.53x
P/FCF
-1.61x
EV/EBITDA
—
Shares Out
133.9M
Financials (TTM)
Revenue
$889K
Net Income
-$74.8M
EBITDA
-$150.4M
Free Cash Flow
-$135.3M
Op Cash Flow
-$120.1M
EPS Basic
$-0.52
EPS Diluted
$-0.55
EPS Forward
$-0.68
Gross Margin
-224.4%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$335.6M
Total Liab.
$34.8M
Total Equity
$300.8M
Cash
$270.0M
LT Debt
$0
Book Value/Sh
$2.25
Debt/Equity
0.00x
Current Ratio
9.13
Quick Ratio
9.13
Returns & Growth
ROE
6.8%
ROA
-20.6%
ROIC
-54.1%
Rev Growth YoY
+1075.0%
EPS Growth YoY
+16.1%
Price Returns
2W
+1.9%
1M
-18.1%
3M
-15.1%
6M
-5.8%
12M
-48.7%
Technicals
52W High
$3.48
52W Low
$1.45
50d MA
$1.73
200d MA
$2.11
RSI (14)
53.50
ATR (14)
$0.08
Beta
1.86
Avg Volume
1.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$4.67
High
$6.00
Low
$3.00
Median
$5.00
Data updated apr 26, 2026 8:47pm
· Source: financialmodelingprep.com